Tempus expands collaboration with Moderna and Merck on cancer therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/20/2026

1. BRZE
2. SPY
3. RAPP
4. META
5. ZION
6. MMM
7. NFLX
8. IBM
9. AMZN
10. TSLA

Go back to Tempus expands collaboration with Moderna and Merck on cancer therapy

Tempus Announces Multi-Year Collaboration with Moderna and Merck

October 7, 2026 8:30 AM EDT

Collaboration to Support Potential Commercialization of Intismeran Autogene

CHICAGO--(BUSINESS WIRE)-- Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Mercks anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The collaboration builds on joint efforts initiated last year and will... More